A number of questions have been raised about the use of the US Environmental Protection Agency's Developmental Neurotoxicity Testing Guideline (DNTG) in the hazard identification of chemicals. The applicability and sensitivity of animal tests in the DNTG relative to human developmental neurotoxicity have recently been questioned. In a workshop held in 1989, participants compared the effects of several known developmental neurotoxicants in humans and animal models and concluded that the DNTG would have detected known human developmental neurotoxicants. They also concluded that although procedural differences may differ in the testing of humans and animals, the neurobiologic functions (ie, autonomic, sensory, motor, and cognitive) affected by chemical exposure were similar. In cases where the DNTG has been compared with other measures of reproductive and developmental toxicity, the DNTG has been relatively sensitive and specific. To date, DNTGs have been required 12 times, for 9 pesticides and 3 solvents. The sensitivity of the measures in the DNTG relative to other measures of developmental and adult toxicity supports the continued use of the DNTG in risk assessment.
INTRODUCTION
Scientists, health officials, and the general public have been concerned for many years about the possible adverse effects of drugs or chemicals in the environment on the development of the nervous system. This concern is based in part on estimates that 70% of developmental defects, which include death, growth retardation, structural alterations, or functional deficits, have no known cause and that exposure to environmental factors during critical periods of development might responsible for some of these defects (38) . In addition, the National Academy of Sciences estimated that 12% of the 63 million children under the age of 18 in the United States suffer from one or more mental disorders, and exposure to toxic substances before or after birth has been identified as one of the several risk factors that may make children susceptible to these disorders (20) . Each day, an estimated 1.1 million children between 6 months and 6 years of age ingest organophosphate insecticides at levels that exceed the safe daily dose as determined by the Environmental Protection Agency (EPA) (33) .
Although the effects of exposure to neurotoxicants in childhood are difficult to assess because of the complex nature of human brain function and the multiple factors that affect brain development (21) , there is ample evi-dence from human and animal experiments that exposure to chemicals and physical factors during development can have adverse consequences on the developing nervous system. Using behavior as an end point, Kimmel (14) identified several agents that are strongly suspected to be human developmental neurotoxicants, including several drugs (ie, ethanol, opiates, cocaine, phenytoin), X-radiation, and environmental agents (eg, lead, methyl mercury, polychlorinated biphenyls [PCBs] ). The risk of human developmental neurotoxicity resulting from drug abuse was also reviewed at a New York Academy of Sciences conference in 1989 (13) .
Animal research has confirmed the conclusion that exposure to drugs and environmental agents during development can have long-term consequences on nervous system structure or function (11, 16, 27) . At a workshop sponsored by the EPA in 1989, participants concluded that (a) there was considerable comparability of end points across species, including humans, for developmental neurotoxicity, (b) animal testing methods in developmental neurotoxicity measured qualitatively similar effects in humans, and (c) quantitative differences between animals and humans are largely due to differing toxicokinetic factors. It was also determined that specific effects produced by chemicals, including neuropathology in adults, nervous system teratogenesis, and hormonal activity, could be used to trigger more extensive developmental neurotoxicity testing (1, 14, 23) . This workshop also reinforced the concern that the potential for chemi-cals to produce adverse effects on the developing nervous system was high and that regulatory processes needed to be in place to screen chemicals for potential developmental neurotoxicity using animal testing protocols required by regulatory agencies.
Although it is generally accepted that exposure to some chemicals during development can adversely affect the nervous system, there is less consensus concerning the adequacy of the current regulatory process to protect infants and children and to identify potential developmental neurotoxicants. Dews (5) indicated that the developing nervous system appears to be sensitive only to a few agents and that it is quite capable of adapting to insult. This observation might be interpreted as suggesting that neurotoxicologic testing in adults may be sufficient to identify potential developmental neurotoxicants. In addition, Lochry (18) noted that screening procedures for developmental neurotoxicity in animals rely heavily on behavioral measures, which may be difficult to interpret, often lack standardization across laboratories, and may not be as sensitive as other indicators of developmental toxicity. Lochry (18) also noted that information concerning developmental neurotoxicity could be obtained from routine assessments in other studies on reproductive or developmental toxicity that include measures of embryo/fetal death, fetal malformation, and delayed development. These concerns are important because inappropriate testing could unfairly impede or block the development of useful products (18) .
In its report on pesticides in the diets of infants and children, the National Research Council (21) concluded that current toxicity testing requirements of the EPA include only a few tests specifically designed to protect infants and children and do not take into account the toxicity or metabolism of chemicals in neonates and adolescent animals nor do they assess the long-term effects of exposure during early developmental stages. The Natural Resources Defense Council (NRDC) (37) has also called for the EPA to review and revise, if necessary, its toxicity testing protocols to ensure that they reliably assess the full range of toxic effects most relevant to infants and children, including effects on the developing nervous, immune, endocrine, and reproductive systems.
The purpose of this article is to address some of the concerns that have been raised about (a) the need to consider the developing experimental animal or human separately from the adult, (b) current testing strategies for developmental neurotoxicity, and (c) salient issues related to risk assessment for infants and children.
TESTING STRATEGIES FOR DEVELOPMENTAL

NEUROTOXICITY Early Test Guidelines
Guidelines for the assessment of developmental neurotoxicity of pharmaceutical agents were introduced in Japan in 1974 and in Great Britain in 1975 (1, 36) . The Japanese requirements are for new drugs and include behavioral assessments of offspring from females exposed during organogenesis (teratology study) and exposure during the last third of gestation and throughout lactation (perinatal study). The Japanese regulations state that behavioral observations can be made by a series of procedures that measure motor capabilities, learning sensibility, or emotion. The 1975 British regulations are part of their studies on reproductive guidelines for new drugs and include the requirement that animals be tested for auditory, visual, and behavioral impairment. The guidelines for Great Britain pertain to studies involving exposure prior to and after conception (fertility studies) and to perinatal studies. In both Japan and Great Britain, the same latitude in the choice of specific behavioral tests is allowed. Regulations concerning developmental neurotoxicity for food additives and industrial or environmental chemicals have not been promulgated in Japan or Great Britain. In 1983, the European Economic Community proposed guidelines for preclinical reproductive and developmental toxicity testing for its member countries. Final guidelines accepted in 1985 call for studies to determine late effects of drugs on the progeny in terms of auditory, visual, and behavioral impairment. General behavioral teratology testing guidelines were proposed by the World Health Organization in 1986 (39) . The Organization of Economic Development and Cooperation recently issued a draft guideline for developmental neurotoxicity testing of drugs and chemicals (22) .
The agency responsible for regulation of drugs in the United States, the Food and Drug Administration, has proposed guidelines for reproduction and developmental toxicity studies that would include developmental neurotoxicity assessments for direct food and color additives. Included in these guidelines are a specific histopathologic examination of tissue samples representative of all major areas and cellular elements of the brain, spinal cord, and peripheral nervous system and a systematic examination of experimental animals inside and outside their cages using a defined battery of functional tests and clinical observations. The objective of the functional assessments is to determine chemical effects on cognitive, sensory, motor, and autonomic function in the mature and developing nervous systems.
Testing Guidelines for Environmental Agents
The EPA first issued a protocol for developmental neurotoxicity testing of environmental chemicals in 1986. These guidelines were devised to assess in rodents the functional and morphologic effects on the nervous system that may arise in the offspring from chemical exposure of the mother during lactation and gestation. The developmental neurotoxicity testing guideline involves a postnatal evaluation of offspring exposed via the mother, including observations to detect gross neurologic and behavioral abnormalities and tests of motor activity, auditory startle, and learning/memory. These guidelines are based on the assumption that nervous system development involves a series of anatomic and functional changes over time, making assessment at multiple time points necessary. In addition, a single measure is considered inadequate to identify a chemical-induced change in neural development. Instead, a battery of tests is needed to sample the various developmental steps indicative of changes in anatomic and functional development. The degree of concordance between anatomic and functional alterations plays an important role in weight of evidence determinations. The developmental neurotoxicity testing guidelines were revised in 1991 (31 ) and more recently in 1998 (32) .
The current EPA protocol requires 20 or more litters of animals per dose group and 3 or more dose groups, plus a vehicle control. Exposure includes dosing the dam from gestational day 6 through postnatal day 10. The EPA developmental neurotoxicity testing protocol is largely based on the results of a Collaborative Behavioral Teratology Study (CBTS) completed in 1985, which involved 6 laboratories studying the developmental effects of 2 chemicals, D-amphetamine and methyl mercury, using a standard battery of tests for sensory, motor, and learning abilities (15) . The conclusions from the CBTS were that behavioral data are reproducible across laboratories if collected under standardized conditions and that the detection sensitivities of the tests used were acceptable, requiring no more than 5-20% change from control values. It was also determined that replication within a study allowed for adequate sample sizes to be tested and that the litter contributed a significant amount of variability to behavioral data, supporting the argument that the litter should be the statistical unit. The collaborative study found that D-amphetamine produced few behavioral or physical effects in the offspring at doses that were not maternally toxic. Gestational exposure to methyl mercury, however, was found by all laboratories to affect startle reactivity in the offspring at doses that were not maternally toxic. The generality of these findings was confirmed in 2 parallel studies (34, 35) in which another battery of tests (Cincinnati Test Battery) was used to assess the 2 chemicals. This battery measured many of the same functions as the CBTS protocol but tended to focus more on measures of neurologic and behavioral development. Kutscher et al (17) also reported several anatomic changes in methyl mercury-treated animals from the CBTS study. These histopathologic data provided support for many of the measures, including morphometric analysis, that are included in EPA's developmental neurotoxicity screening battery (32) . In general, the CBTS results indicated that behavioral tests can be sensitive, reliable measures of developmental neurotoxicity if protocols are standardized and trained personnel are used to conduct the study.
At a subsequent workshop, a number of critical issues for assessing developmental neurotoxicity testing were addressed, including the comparability of end points across species for developmental neurotoxicity, testing methods in developmental neurotoxicity for use in human risk assessment, weight-of-evidence and quantitative evaluation of data from developmental neurotoxicity studies, and triggers for developmental neurotoxicity testing (16) . Participants in this workshop were asked to review the human and experimental animal data on agents known to cause developmental neurotoxicity in humans, including lead, methyl mercury, phenytoin, drugs of abuse, PCBs, ethanol and ionizing radiation. There was a consensus among the participants in the various breakout groups that the EPA developmental neurotoxicity testing protocol would have identified each of the agents discussed at the meeting (9) . Each agent had clear effects in rodents that would have been observed in 1 or more measures used in the EPA protocol. Participants also concluded that for functional data (sensory, motivational, cognitive, and motor function and social behavior), there was close agreement across species for all neurotoxic agents reviewed (29) .
Workshop particiapants also determined that animal tests are adequate for making comparisons with humans and that quantitative differences between animals and humans are most likely due to differing toxicokinetic variables. There was also agreement that the assessment of developmental neurotoxicity should involve an evaluation of multiple categories of function, which supports the broad behavioral testing battery described in the current EPA developmental neurotoxicity testing guidelines (32) . Many of the tests described by the participants as being sensitive to known human developmental neurotoxicants are included in the EPA's developmental neurotoxicity testing guidelines. For the chemicals discussed, behavioral effects frequently were observed at doses below those required to produce maternal toxicity. This observation supports the use of a high dose that is at or just below the threshold for the production of minimal maternal toxicity (32) . In addition, there was support for the assessment of various functions at different points in the life span of the animal.
Lochry (18) suggested that end points used in routine developmental and reproductive toxicity studies could provide the data necessary to determine if a compound has the potential to cause developmental neurotoxicity in humans. This hypothesis was further tested by Faber and O'Donoghue (8) , who reported that 37 of the 41 developmental neurotoxicants they surveyed could be detected by the Chemoff/Kavlock assay, a battery of tests originally designed as a postnatal screen for developmental toxicity, including teratogenicity and fetotoxicity. This assay includes measures of birth weight, neonatal growth to postnatal day 3, fetal viability, and neonatal survivability and is much less comprehensive than the developmental neurotoxicity testing guidelines. Faber and O'Donoghue concluded that the developmental neurotoxicity testing guidelines may not be necessary because such chemicals could be detected in routine developmental toxicity testing protocols. However, Goldey et al (10) argued that the 41 chemicals selected by Faber Makris et al found that there were treatment-related effects on the nervous system for 7 of the 9 pesticides, but for DEET and Chemical X, findings in the offspring were limited to changes in motor activity at the highest dose tested. For the solvent TGME, alterations in startle reactivity were observed at the highest dose tested, but no effects on the offspring were observed for the other 2 solvents. Significant decreases in brain weight were noted with 5 of the 9 pesticides, and treatment-related morphometric alterations were noted for 3 of the 6 pesticides for which such data were provided.
Makris et al (19) also found that the NOAEL for developmental neurotoxicity was lower than or about equal to NOAELs for acute and/or subchronic neurotoxicity in adult animals for 6 of the 9 pesticides. For 8 of the 9 pesticides, the NOAEL for developmental neurotoxicity was lower than that of the fetal NOAEL from prenatal developmental toxicity studies and was equivalent for the remaining chemical. In addition, for 2 of the 9 pesticides, the NOAEL for developmental neurotoxicity was lower than or equal to that for any adult or offspring end point from prenatal developmental, reproduction, or neurotoxicity studies. These observations indicate that the developmental neurotoxicity test battery is capable of detecting hazards and generating dose-response relationships that could be useful in evaluating chemicals for potential human developmental neurotoxicity. These results further support the conclusion that the developmental neurotoxicity test battery is as sensitive as or more sensitive than reproductive and developmental toxicity protocols. Although EPA's developmental neurotoxicity testing battery appears to be relatively sensitive to developmental neurotoxicants and provides data for rodents that allow evaluation of the full range of potential neurotoxic effects in humans (ie, sensory, motor, learning/memory, developmental milestones, sexual maturation), there are several issues that remain problematic concerning the use of this battery of tests in a screening context. One notable concern is that the developmental neurotoxicity test battery is not currently required for the registration of a food-use chemical. For any chemical that is registered for food use, 2 developmental toxicity studies (rodent and nonrodent) and a 2-generation reproduction study in rats are required. The developmental toxicity protocol exposes mothers only during the prenatal period, whereas the reproductive study includes some postnatal indirect exposure, through breast milk. Offspring of exposed mothers are not evaluated for nervous system structural or functional changes in the reproductive study. A 90-day neurotoxicity study in adult rats may be required, depending on the outcome of the acute toxicity studies or on structure-activity relationship considerations. Acute or subchronic delayed neurotoxicity testing in hens may be required if the substance is an organophosphate or a metabolite or degradation product that may cause inhibition of acetylcholinesterase or if the substance is structurally related to a chemical that causes delayed neurotoxicity.
Under certain circumstances, a developmental neurotoxicity study may be required. The decision to require such testing is based on criteria or triggers from both adult and developmental toxicity data and a weight-of-evidence review of all available data for each chemical. Triggers for developmental neurotoxicity testing include neuropathy/ neurotoxicity in adults, hormonal activity, or other types of developmental toxicity. As pointed out by the NRDC (37) , this tiered testing strategy has rarely led to the use of the developmental neurotoxicity testing protocol. In fact, the developmental neurotoxicity testing guideline has only been required for the 12 chemicals surveyed by Makris et al (19) .
The EPA's developmental neurotoxicity testing protocol exposes mothers from gestational day 6 through postnatal day 10 . The development of the brain continues well after birth in both experimental animals and humans, and it has been argued that termination of exposure at postnatal day 10 is not adequate (37) . Organogenesis and histogenesis are completed prenatally in the rat, and neurogenesis and migration are complete by postnatal day 10 (1). Synaptogenesis, gliogenesis, and myelination also begin prenatally in the rat but are not complete until maturity. However, brain weight in the rat is more than 80% of maturity at postnatal day 21 or weaning in most strains (21) , and all postural, locomotor, and related skills have developed by this time (1) . Postnatal day 21 in the rat is approximately equivalent to 2 years of age in the human (21) , and exposure up to weaning in the rat could be sufficient to model exposure in infants and young children. Unfortunately, there are few studies that have actually compared effects in studies terminated at postnatal day 11 with those from studies using a long postnatal exposure period. In the studies reviewed by Makris et al (19) , dosing was extended to weaning for DEET, emamectin, TGME, and isopropanol, and there were no obvious effects that could be related to late lactation dosing of the offspring via the diet and/or maternal milk. All of these observations support the suggestion that the dosing period in the developmental neurotoxicity protocol should be extended to at least postnatal day 21. It has also been argued that the developmental neurotoxicity protocol fails to assess test animals for a long enough period to detect delayed, or latent, effects of toxicity on the developing brain (37) . The developmental neurotoxicity testing protocol terminates testing at about postnatal day 60-62, which is well beyond sexual maturity in the rat. Developmental exposure to neurotoxic compounds may be followed years or decades later by clinically evident neurologicadisease (26) . Although the importance of life-long assessment has been repeatedly demonstrated in humans, such studies are relatively rare in neurotoxicology. Early exposure to chemicals may increase the risk for neurologic diseases that typically develop later in life, such as Alzheimer's or Parkinson's diseases, but experimental data to support this hypothesis are scarce. Several animal studies have indicated that developmental exposure to chemicals such as triethyltin or methyl mercury can have long-lasting effects on the nervous system. However, in these studies, developmental exposure resulted in functional alterations early in life, which were followed by an appearance of new signs or exacerbation of existing signs as a function of aging. In the context of screening chemicals for potential developmental neurotoxicity, such effects would have been detected using a battery similar to the developmental neurotoxicity testing protocol. In the study by Barone et al  (3) , rats were dosed with triethyltin on postnatal day 10 and examined across the life span for anatomic damage and functional deficits. In neonatal rats, histologic examination indicated gliosis in the neocortex and loss of neurons in the hippocampus. In addition, significant impairment was detected from the results of a spatial maze test at postnatal day 23. Such effects would most likely have been identified by the developmental neurotoxicity testing protocol. Significant impairments in spatial learning, however, were not observed at 3 or 12 months of age, although at 2 years of age, the triethyltin-treated animals performed more poorly than did age-matched controls, suggesting an exacerbation of the triethyltin effect with aging. Although the possibility of accelerated aging produced by early exposure to an environmental chemical is a crucial finding, it does not suggest that the developmental neurotoxicity testing protocol is insensitive to the developmental neurotoxic effects of triethyltin. There is scarce information showing no anatomic or functional changes up to 60 days of age followed by the appearance of neurotoxicity that resembles neurodegenerative diseases such as Alzheimer's or Parkinson's diseases late in life.
Although this area remains a fruitful one for future research, life-time longitudinal assessments in developmental studies do not seem warranted at this time.
Another concern that has been raised is that the EPA's requirements for the registration and reregistration of pesticides include no testing for disruption of the endocrine system (37) . In addition, the NRC report (21) recommended that serum thyroid hormones T3 and T4 and serum thyroid-stimulating hormone be routinely added to the EPA chronic carcinogenicity study protocol or to the subchronic toxicity protocol for the rat so that adverse effects on thyroid function can be determined earlier. The Food Quality Protection Act (FQPA) and amendments to the Safe Drinking Water Act provide the legislative basis for developing and implementing a strategy for screening and testing chemicals for endocrine disruption. The EPA's Endocrine Disruptor Screen and Testing Advisory Committee (EDSTAC) has recommended a tier I screening battery to evaluate the potential for chemicals to act as activators or repressors of the estrogen, androgen, and thyroid receptors using in vitro cell reporter assays. Recommended in vivo tests include a uterotrophic assay to examine effects mediated by the estrogen receptor and an assay to evaluate effects on androgen receptor function. The EDSTAC also recommended additional tests (tier 2) to characterize the nature, likelihood, and dose-response relationship of endocrine disruption of estrogen, androgen, and thyroid activity in humans and wildlife. For purposes of screening, a 2-generation reproduction study probably will be adequate for this purpose. There is no evidence that chemicals that act on neuroendocrine development would be missed by the proposed 2-tier testing strategy or that the developmental neurotoxicity testing protocol should be required for such chemicals. In summary, EPA's developmental neurotoxicity testing protocol measures a full range of neurobiologic functions in animals, and these data appear to extrapolate well to humans. The battery appears to be sensitive to known developmental neurotoxicants, and the results obtained are sensitive relative to other measures of developmental and reproductive toxicity. Measures of neurotoxicity in adult animals are not sufficient to predict changes in developing animals. The developmental neurotoxicity testing protocol has been used infrequently, and other measures of developmental and reproductive toxicity are not fully sensitive to developmental neurotoxicity. There is scientific and logistical support for extending the postnatal dosing period to weaning. The possible relationship between early exposure and increased risk of neurodegenerative disease deserves additional research, but there are insufficient data to support the use of life-time observations in the current testing protocol. Proposed in vitro and in vivo tests for endocrine system disruption appear sufficient to detect chemicals that may alter neuroendocrine function during development.
RISK ASSESSMENT ISSUES
The purpose of risk assessment is to set acceptable levels of exposure. The process typically begins with a determination of a critical adverse effect based on the evaluation of all available human and experimental ani-mal data. An estimate of daily exposure to the human population that is likely to occur without appreciable risk over a lifetime is called the reference dose (RfD) or reference doncentration (RfC) (2) . Calculation of the RfD/ RfC is based on determination of a NOAEL or a LOAEL from a critical study or studies. The LOAEL is defined as the lowest dose at which there is a statistically or biologically significant increase in the incidence of an adverse effect. The NOAEL is defined as the highest dose at which there is no statistically significant increase in the presence of an adverse effect.
Historically, derivation of the RfD/RfC is based on dividing the NOAEL or LOAEL by safety or uncertainty factors to account for variation in sensitivity among members of the human population, animal-to-human extrapolation, less-than-lifetime exposure, and extrapolating from a LOAEL to the NOAEL in the absence of a NOAEL. In addition, modifying factors may be added to account for scientific uncertainties such as the quality or completeness of the data set. The default value for the uncertainty factors is 10, but it may be reduced depending on the availability of other information. Dose-response data from human and animal studies may also be expressed by determining an effective dose (ED) estimated for a given level of response, eg, the ED 10 would be the effective dose that produces a 10% change in response.
The lower confidence interval associated with the estimate of the ED is defined as the benchmark dose (BMD).
Analysis of dose-response data from developmental studies is conducted as part of the overall dose-response evaluation of all available human and animal data. The NOAEL or BMD may also be divided by the estimate of the human exposure to derive a margin of exposure to determine if there are adequate controls on exposure to humans. Although exposure in developmental protocols involves repeated dosing pre-and/or postnatally, it is assumed that adverse developmental effects may be produced by a single exposure during a critical period of development.
In the NRC report on pesticides in the diets of infants and children (21) , concerns were raised about the ability of the current risk assessment process to adequately protect infants and children from the adverse effects of pesticide exposure. There are several reports in the literature to support the application of a 10-fold factor to protect 80-95% of the population (4, 6, 7, 12) . In addition, Sheehan and Gaylor (28) reported that in 86% of the cases, the ratios of LDsos of adult to young animals for 238 chemicals were less than 10. Renwick and Lazarus (25) also found that the toxicokinetics of infants and children do not differ by an order of magnitude from adults, and Renwick (24) concluded from a comparative study of toxicokinetics of young and adult animals and humans that a 10-fold intraspecies factor may provide adequate protection. The NRC agreed that although the intraspecies uncertainty factor for variation within the human population generally provides adequate protection for infants and children, this population may be uniquely susceptible to chemical exposure at critical states of development. Because of specific periods of vulnerability during development, the NRC recommended that an addi-tional uncertainty factor of 10 be considered when there is evidence of postnatal developmental toxicity and when data from toxicity testing relative to infants and children are incomplete. The NRC also indicated (21) that a new, additional uncertainty factor was not necessary. Instead, the NRC committee recommended an extension of an uncertainty factor, now routinely applied by agencies, related to completeness of the data set. The NRC recommendation is based on the assumption that in the absence of data to the contrary infants and children should be considered to be more sensitive to chemicals, such as pesticides, than adults. In response to the concern about the safety of infants and children, the US Congress passed the FQPA (in 1996), which stipulates that for threshold effects, an additional 10-fold margin of safety for other chemical residues and other sources of exposure must be applied for infants and children to take into account potential pre-and postnatal toxicity and completeness of data with respect to exposure and toxicity for infants and children.
The EPA has on occasion used an uncertainty factor applied to the RfD to account for deficiencies in the available data set. According to Dourson et al (6) , if data on children's health are not adequate, then an uncertainty factor has been used to account for such deficiencies. A modifying factor of 3 may be applied if either a prenatal toxicity study or a 2-generational reproduction study is missing, or a factor of 10 may be applied if both are missing. A database uncertainty factor has not been applied in the past for the lack of developmental neurotoxicity data. Inclusion of the developmental neurotoxicity testing protocol in the core set of required tests should alleviate the need to consider an additional uncertainty or safety factor for the absence of developmental neurotoxicity data. In general, the size of the uncertainty factor for completeness of the data set will ultimately depend on all available information and how much impact the missing data may have on estimating the toxicity of the chemical to infants and children.
In summary, concern about the ability of the regulatory process to adequately protect infants and children led to the passage of the FQPA of 1996. Based largely on recommendations from a NRC report on pesticides in the diets of infants and children, regulatory agencies such as the EPA must now consider an additional safety factor that would protect infants and children, taking into account their potentially greater vulnerability and their unique patterns of exposure. The application of such a safety factor depends on the completeness of the data base. The EPA has been criticized (37) for not using this additional safety factor more frequently in considering pesticide tolerances; it has applied a 10-fold factor in only about 10% of the over 100 decisions. What constitutes a &dquo;reliable&dquo; or &dquo;complete&dquo; database to be used in the application of such a safety factor continues to stir debate.
SUMMARY AND CONCLUSIONS
The potential vulnerability of infants and children has led to the development of testing guidelines for both pharmaceuticals and environmental chemicals. Recently, the approach taken by regulatory agencies such as the EPA to protect infants and children from overexposure to pesticides and other chemicals has been criticized. One major concern is that although a mechanism is in place to trigger developmental neurotoxicity testing on the basis of results from a core battery of toxicity tests, the developmental neurotoxicity testing battery has been used only infrequently. Another concern is that the developmental neurotoxicity testing protocol may not include tests appropriate for evaluating developmental effects in infants and children and may not be sensitive to developmental neurotoxicants. The developmental neurotoxicity testing battery includes measures of sensory, motor, and cognitive development and was validated several years ago by the CBTS. Participants in a workshop held in 1989 compared the effects of several known developmental neurotoxicants in humans and in animal models and concluded that the developmental neurotoxicity testing battery would have detected all of the chemicals discussed. In addition, it was determined that animal models measure qualitative similarities between animals and humans, although quantitative differences due to toxicokinetic and other factors are apparent. In cases where the developmental neurotoxicity testing protocol has been compared with other measures of reproductive and developmental toxicity and adult neurotoxicity testing, it has been shown to be relatively sensitive and specific.
Although there is evidence that application of an uncertainty factor for intrapopulation variability may be sufficient to protect most of the population, including infants and children, a report by the NRC (21) has raised concern about the differential vulnerability of infants and children during critical phases of development This concern led to the passage of the FQPA in 1996, which mandates that, depending on the adequacy of the available data, an additional safety factor must be considered to protect infants and children. The actual application of such a safety factor in the evaluation of over 100 pesticides has not been excessive (about 10%), which has stimulated considerable debate and discussion concerning the definition what constitutes &dquo;reliable data&dquo; on children's toxicity and exposure to chemicals such as pesticides. ACKNOWLEDGMENT This article has been reviewed by the National Health and Environmental Effects Research Laboratory, US Environmental Protection Agency, and approved for publication. Mention of trade names or commercial products does not constitute endorsement of recommendation for use.
